Teva gets close-out letter over Jerusalem plant

Teva Pharmaceutical ($TEVA) has received a close-out letter from the FDA stating the generics giant has addressed issues raised after an inspection of its Jerusalem plant.

The close-out reflects remediation actions taken at the oral solid dosage plant following Teva's receipt of a warning letter in January. A June re-inspection by the FDA resulted in no adverse findings. "Based on our evaluation, it appears that you have addressed the violation(s) contained in this warning letter," the close-out letter says.

Earlier this year, Teva restarted production at its Irvine, CA, plant, following remediation efforts.

So far in 2011, with 450 warning letters issued across all FDA categories, only 26 have garnered close-out letters. The FDA says on its website that "a close-out letter may issue when, based on the FDA's evaluation, the firm has taken corrective action to address the violations contained in the Warning Letter."

Six of this year's close-out letters concern pharma products; 16 fall in the highest-closeout category: food.

- here's the story
- see the Close-out Letter
- here's Warning Letter 320-11-008


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.